This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E83.1 (disorders of iron metabolism) | Special Copayment Reduction: V255 |
| B. Synonyms | Hemochromatosis, hereditary hemochromatosis, HFE-related hemochromatosis, primary hemochromatosis, Bronze diabetes |
| C. Adult onset | Possibility of first onset in adulthood: very high — in hereditary hemochromatosis, iron accumulates slowly over decades before organ damage appears, so clinical symptoms typically first appear in men mainly in their 40s–60s and in women after menopause. Onset in childhood or adolescence is rare. |
| 1. History | 1865 first description by Trousseau; 1996 HFE gene (C282Y) identified; mechanism established with the discovery of hepcidin |
| 2. Causes | HFE gene variants (C282Y homozygosity, etc.) → dysregulation of hepcidin → excessive intestinal iron absorption → iron deposition in the liver, pancreas, heart, joints, and skin |
| 3. Genetics | Autosomal recessive; HFE (6p21.3); C282Y/C282Y homozygosity is the most common cause in people of Northern European descent; low clinical penetrance |
| 4. Epidemiology | C282Y homozygosity frequency 1/200–250 (Northern European descent); symptom manifestation rate <10%; rare in people of Asian descent |
| 5. Pathophysiology | HFE variants → decreased hepcidin secretion → ferroportin overexpression → increased intestinal iron absorption → elevated serum transferrin saturation → non-transferrin-bound iron (NTBI) → deposition in the liver, heart, and pancreas |
| 6. Symptoms | Fatigue, arthralgia (2nd and 3rd metacarpophalangeal joints), abdominal discomfort, erectile dysfunction/amenorrhea, cardiac symptoms (arrhythmia, heart failure) |
| 7. Signs | Bronze skin, hepatosplenomegaly, diabetes (Bronze diabetes), cardiomegaly, articular cartilage calcification |
| 8. Screening | Fasting serum transferrin saturation (>45%) and serum ferritin; family screening; liver function tests |
| 9. Diagnosis | HFE gene C282Y/H63D testing; iron quantification by liver biopsy (MRI); diagnosis possible before symptoms |
| 10. Treatment | Therapeutic phlebotomy (bloodletting); chelating agents (deferoxamine/deferasirox); liver transplantation (end stage) |
| 11. Prognosis | Normal life expectancy with early treatment before cirrhosis develops; persistent risk of hepatocellular carcinoma after cirrhosis |
| 12. Prevention | Family screening tests; early phlebotomy; avoid iron supplements and excessive vitamin C intake; limit alcohol |
| 13. References | List of key PMIDs and DOIs |
The first clinical description of Hereditary Hemochromatosis (HH) dates back to the French internist Armand Trousseau in 1865. He described a case showing the triad of hepatosplenomegaly, diabetes, and skin pigmentation. In 1882, the German pathologist Friedrich Daniel von Recklinghausen confirmed iron overload histologically and first used the name "Hämochromatose". In 1935, Joseph Sheldon proposed that the disease has a genetic origin and is a disorder of iron metabolism. The mode of inheritance of iron overload (autosomal recessive) was subsequently gradually established through family studies. 1996 was a landmark turning point in hemochromatosis research, when Feder et al. discovered the HFE gene located on the short arm of chromosome 6 (6p21.3) and its specific variants (C282Y, H63D), making molecular diagnosis possible. Subsequently, hepcidin was discovered in 2001, and the mechanism by which HFE variants increase intestinal iron absorption through dysregulation of hepcidin was elucidated over the 2000s. Currently, in addition to the HFE type (type 1), non-HFE hemochromatosis due to variants in the hemojuvelin (HJV), hepcidin (HAMP), transferrin receptor 2 (TFR2), and ferroportin (SLC40A1) genes has been described.
The most common cause of hereditary hemochromatosis is the homozygous state of the C282Y (p.Cys282Tyr) variant of the HFE gene (6p21.3). This single variant explains 80–90% of hemochromatosis in people of Northern European descent. The second most common is C282Y/H63D compound heterozygosity, which causes mild iron overload in some patients. H63D homozygosity alone mostly does not cause clinical hemochromatosis. The HFE protein interacts with transferrin receptor 1 (TfR1) and is involved in the signaling pathway that promotes expression of hepcidin (the HAMP gene product) in hepatocytes. The C282Y variant disrupts the disulfide bond between the HFE protein and beta-2 microglobulin, preventing the protein from being normally expressed on the cell surface. As a result, hepcidin expression decreases, inhibition of ferroportin by hepcidin is released, and iron release into the blood from small intestinal epithelial cells and macrophages increases excessively. With increased iron absorption, iron is excessively deposited over decades in the liver, pancreas, heart, joints, pituitary gland, and elsewhere.
Hereditary hemochromatosis follows an autosomal recessive mode of inheritance. The HFE gene is located on the short arm of chromosome 6 (6p21.3) near the HLA complex. C282Y homozygosity accounts for most HFE hemochromatosis (type 1) and shows a high homozygote frequency of about 1/200–250 in people of Northern European descent. The heterozygous carrier frequency reaches about 1/8–10. The C282Y variant is very rare in Asians (Korea, Japan, China) and Africans. Iron overload in Asian populations should prompt consideration of non-HFE causes (SLC40A1, TFR2, HJV, etc.). The clinical penetrance of HFE hemochromatosis is very low: large cohort studies have found that only about 28% of C282Y homozygous men and about 1–2% of women experience hemochromatosis-related organ damage. The low penetrance is understood to be due to the influence of dietary iron intake, blood loss (menstruation in women), alcohol consumption, other modifier genes, and so on. Non-HFE hemochromatosis (types 2A/2B/3/4) is much rarer and tends to be more severe.
HFE-related hereditary hemochromatosis is one of the most common autosomal recessive genetic diseases in white people of Northern European descent. The C282Y homozygosity frequency is very high at 1/200–250 in people of Northern European descent, so it can be considered a common genetic disease in this population. However, because clinical penetrance is very low (28% in men, 1–2% in women), far fewer patients actually develop symptoms. Clinical manifestation is 4–5 times more common in men than in women, because iron loss due to menstruation in women partly offsets excess accumulation. In women, iron overload symptoms appear mainly after menopause. The HFE C282Y variant is very rare in Asian, African, and Hispanic populations, so the epidemiology of hemochromatosis differs. The frequency of HFE variants in the Korean population is markedly lower than in Europe, and the number of registered patients with hereditary hemochromatosis in Korea is small. In modern times, with increasing consumption of iron-fortified foods and supplements, dietary factors may contribute to the expression of the iron overload phenotype.
Normally, hepcidin is synthesized and secreted by the liver and binds to ferroportin, the only iron export protein, located on the basolateral membrane of small intestinal epithelial cells and macrophages, internalizing and degrading ferroportin and thereby suppressing iron release into the blood. When HFE protein function is lost due to HFE variants (C282Y homozygosity), the signals for hepcidin synthesis (signaling through the BMP-SMAD pathway and the HFE-TfR2 complex) decrease, and hepcidin secretion remains inappropriately low. When hepcidin is low, ferroportin is continuously expressed, and iron release from the small intestine into the blood increases excessively. When serum transferrin becomes supersaturated, non-transferrin-bound iron (NTBI) is generated and is directly taken up and deposited in hepatocytes, cardiomyocytes, pancreatic beta cells, joint synovial cells, and pituitary cells. Excess intracellular iron generates reactive oxygen species (ROS) through the Fenton reaction, causing lipid peroxidation, DNA damage, and protein oxidation, ultimately leading to cell death and tissue fibrosis.
Early symptoms: Fatigue (the most common symptom), arthralgia (arthralgia of the 2nd and 3rd metacarpophalangeal (MCP) joints is particularly characteristic), and abdominal discomfort appear gradually over years to decades.
Hepatic symptoms: Progresses from abnormal liver function (AST/ALT elevation) to fatty liver, liver fibrosis, and cirrhosis. After cirrhosis, the risk of hepatocellular carcinoma (HCC) increases more than 20-fold compared with the general population.
Endocrine symptoms: Hypogonadism develops due to iron deposition in the pituitary and testes, causing erectile dysfunction and decreased libido in men and amenorrhea and early menopause in women. Damage to pancreatic beta cells causes diabetes ("Bronze diabetes").
Cardiac symptoms: Cardiomyopathy, arrhythmias (atrial fibrillation, conduction disorders), and heart failure develop, and these were the main causes of death in severe hemochromatosis before treatment.
Skin symptoms: Generalized skin pigmentation (increased melanin + hemosiderin deposition) causes the characteristic bronze skin discoloration.
The main signs on physical examination and testing are as follows.
Skin findings: Bronze to gray pigmentation is observed over the whole body, especially on exposed areas and in the axillae.
Liver findings: Hepatomegaly, and with progression splenomegaly, ascites, jaundice, and spider angiomata appear.
Joint findings: Tenderness, swelling, and limited motion of the 2nd and 3rd MCP joints; radiographs show articular cartilage calcification (chondrocalcinosis) and subchondral erosion.
Cardiac findings: Abnormal heart sounds, arrhythmia (electrocardiogram), and cardiomegaly (echocardiography) are identified.
Endocrine findings: Testicular atrophy, gynecomastia (when accompanied by cirrhosis), abnormal fasting blood glucose.
Blood tests: Fasting transferrin saturation >45% (men >50%, women >45%); markedly elevated serum ferritin (men >300 ng/mL, women >200 ng/mL); abnormal liver function; confirmation of HFE C282Y homozygosity.
Liver MRI: Decreased liver signal is observed on T2*/GRE sequences and is used for noninvasive quantification of iron deposition.
The most effective tool for screening for hereditary hemochromatosis is measurement of fasting transferrin saturation (TS). When TS >45% is repeatedly confirmed, HFE gene testing is performed. Serum ferritin reflects iron stores, but as an acute-phase reactant it can be nonspecifically elevated by infection, inflammation, fatty liver, alcohol consumption, and so on, so its specificity as a sole screening marker is low. Regarding population screening, opinions differ among international guidelines in view of cost-effectiveness and low penetrance, but screening of first-degree relatives (siblings, children) is strongly recommended by all guidelines. In family screening, TS + ferritin + HFE C282Y/H63D gene testing are performed together. In adult patients with unexplained symptoms such as abnormal liver function, fatigue, arthralgia, diabetes, and cardiac arrhythmia, TS measurement is the basic screening step.
HFE gene testing: When C282Y homozygosity or C282Y/H63D compound heterozygosity is confirmed, HFE hemochromatosis is diagnosed. HFE testing must always be interpreted together with TS elevation and the clinical context.
Quantification of iron overload: Liver iron concentration (LIC) is noninvasively quantified by liver MRI (T2* or R2/R2* techniques). Liver biopsy is used for tissue iron quantification (>36 µmol/g Fe per dry weight = 2,000 µg/g or more) and fibrosis staging, but its necessity is decreasing with advances in MRI.
Indicators for assessing iron overload: Serum ferritin >1,000 ng/mL or the presence of fibrosis on liver biopsy is important for assessing the risk of organ damage. Liver evaluation (MRI or biopsy) is recommended when ferritin is 1,000 ng/mL or more or when accompanied by abnormal liver enzymes.
Suspected non-HFE type: When TS and ferritin are elevated but HFE testing is negative, especially in people of Asian descent or with a family history, a non-HFE hemochromatosis (HJV, HAMP, TFR2, SLC40A1) gene panel test is considered.
Therapeutic phlebotomy: The most effective and safe standard treatment for hereditary hemochromatosis. Each phlebotomy removes 450–500 mL of blood (about 200–250 mg of iron). In the initial treatment (induction phase), phlebotomy is performed weekly or every other week to lower serum ferritin to below 50 ng/mL (target: 20–50 ng/mL). In maintenance treatment (maintenance phase), ferritin is kept within the target range with one phlebotomy every 3–4 months. In patients without cirrhosis before phlebotomy, fatigue, liver function, arthralgia, and so on improve markedly after treatment, and life expectancy normalizes.
Chelation therapy: In patients for whom phlebotomy is not possible (severe anemia, end-stage heart failure, etc.), deferoxamine (intravenous or subcutaneous injection) or deferasirox (oral) is used as an alternative.
Liver transplantation: Liver transplantation may be needed in patients with end-stage cirrhosis or hepatocellular carcinoma. Because the HFE variant persists after transplantation, maintenance treatment such as phlebotomy must be continued.
Dietary control: Avoid excessive intake of red meat and alcohol, iron supplements, and excessive vitamin C (which promotes iron absorption).
With early diagnosis and regular phlebotomy treatment, the life expectancy of hereditary hemochromatosis patients is almost the same as that of the general population. When treatment is started before cirrhosis, diabetes, or cardiomyopathy develops, organ damage is mostly prevented or reversed. Normalization of liver function, improvement of fatigue, reduction of skin pigmentation, and improvement of cardiac function are observed after treatment. However, cirrhosis that has already developed does not fully recover even after treatment, and the risk of hepatocellular carcinoma (HCC) remains persistently high in patients with cirrhosis. Accordingly, in hemochromatosis patients with cirrhosis, an HCC surveillance program at 6-month intervals using liver ultrasound + AFP is essential. Diabetes, joint damage, and hypogonadism are often difficult to fully recover even after phlebotomy treatment. In patients who do not receive treatment or have low adherence, the risk of premature death from cirrhosis, liver failure, heart failure, and diabetic complications is high.
The main prevention strategies for hereditary hemochromatosis are diagnosis before symptom onset (early detection) and family screening. TS, ferritin, and HFE gene testing are performed in all first-degree relatives (siblings, children) of confirmed patients to detect asymptomatic C282Y homozygotes early. When elevated TS or ferritin is confirmed in asymptomatic C282Y homozygotes, preventive phlebotomy is started to prevent organ damage in advance. Through dietary management, avoid excessive intake of red meat, iron supplements, and high-dose vitamin C, and limit alcohol intake (alcohol increases iron absorption and causes double damage to the liver). Even in countries with blood donation restrictions, programs using therapeutic phlebotomy blood from hemochromatosis patients for transfusion are in operation in some countries. Regarding population-based screening, evidence of cost-effectiveness is accumulating, but few countries have yet adopted it as a national standard policy.